GPER blockers as Nox downregulators: A new drug class to target chronic non-communicable diseases.
Oxidative stress is a hallmark of chronic non-communicable diseases such as arterial hypertension, coronary artery disease, diabetes, and chronic renal disease. Cardiovascular diseases are characterized by increased production of reactive oxygen species (ROS) by NAPDH oxidase 1 (Nox1) and additional Nox isoforms among other sources. Activation of the G protein-coupled estrogen receptor (GPER) can mediate multiple salutary effects on the cardiovascular system. However, GPER also has constitutive activity, e.g. in the absence of specific agonists, that was recently shown to promote hypertension and aging-induced tissue damage by promoting Nox1-derived production of ROS. Furthermore, the small molecule GPER blocker (GRB) G36 reduces blood pressure and vascular ROS production by selectively down-regulating Nox1 expression. These unexpected findings revealed GRBs as first in class Nox downregulators capable to selectively reduce the increased expression and activity of Nox1 in disease conditions. Here, we will discuss the paradigm shift from selective GPER activation to ligand-independent, constitutive GPER signaling as a key regulator of Nox-derived oxidative stress, and the surprising identification of GRBs as the first Nox downregulators for the treatment of chronic non-communicable diseases.
Institute of Primary Care, University of Zurich, Switzerland; Division of Cardiology, Triemli City Hospital, Zurich, Switzerland. Electronic address: matthias.meyer@triemli.zuerich.ch.
Matthias R
MR
Meyer
Molecular Internal Medicine, University of Zurich, Zurich, Switzerland. Electronic address: barton@access.uzh.ch.
Matthias
M
Barton
D000818:Animals; D002908:Chronic Disease; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000073296:Noncommunicable Diseases / Q000188:drug therapy*; D018384:Oxidative Stress / Q000187:drug effects; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
D004791:Enzyme Inhibitors; D043562:Receptors, G-Protein-Coupled; D019255:NADPH Oxidases
Estrogen; GPR30; NADPH oxidase; Oxidative stress; Superoxide; Vascular